References
- Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
- Tefferi A, Vardiman J W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22
- Onida F, Kantarjian H M, Smith T L, Ball G, Keating M J, Estey E H, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849
- Gonzàlez-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespì T, Massagué I. Two groups of chronic myelomonocytic leucemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res 2002; 26: 821–824
- Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 1998; 22: 871–878
- Noesslinger T, Reisner R, Gruner H, Tuchler H, Nowotny H, Pittermann E. Dysplastic versus proliferative CMML. A retrospective analysis of 91 patients from a single institution. Leuk Res 2001; 25: 741–747
- Voglovà J, Chrobak L, Neuwirtovà R, Malaskovà V, Straka L. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukaemia: distinct subgroups or two stages of the same disease. Leuk Res 2001; 25: 493–499
- Breccia M, Latagliata R, Mengarelli A, Biondo F, Mandelli F, Alimena G. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. Haematologica 2004; 89: 866–868
- International Standing Committee on Human Cytogenetic Nomenclature. An International System for Human Cytogenetic Nomenclature, F Mittelman. S. Karger AG, Basel, Switzerland 1995
- Mufti G J, Stevens J R, Oscier D G, Hamblin T J, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433
- Sanz G F, Sanz M A, Vallespi T, Canizo M C, Torrabadella M, Garcia S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408
- Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
- Rigolin G M, Cuneo A, Roberti M G, Bardi A, Castoldi G. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 1997; 82: 25–30
- Castoldi G, Rigolin G M. The monocytic component in myelodysplastic syndromes. Cancer Treat Res 2001; 108: 81–92
- Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 2006; 47: 417–423
- Ohyashiki K, Yokoyama K, Kimura Y, Ohyashiki J H, Ito T, Kuratsuji T, et al. Myelodysplastic syndromes evolving into myeloproliferative disorders: one disease or two. Leukemia 1993; 7: 388–340
- Verhoef G EG, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M, et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 1991; 63: 235–241
- Verhoef G EG, Demuynck H, Zacheè P, Boogaerts A. Myelodysplastic syndromes evolving into myeloproliferative disorders: one disease or two. Leukemia 1994; 8: 714–715
- Rosati S, Mick R, Xu F, Stonys E, Le Beau M M, Larson R, Vardiman J W. Refractory cytopenia with multilineage dysplasia: further characterization of an ‘unclassifiable’ myelodysplastic syndrome. Leukemia 1996; 10: 20–26